ClinVar Miner

Submissions for variant NM_002878.4(RAD51D):c.145-3C>T

gnomAD frequency: 0.00001  dbSNP: rs201974522
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Color Diagnostics, LLC DBA Color Health RCV000584627 SCV000691311 likely benign Hereditary cancer-predisposing syndrome 2017-04-24 criteria provided, single submitter clinical testing
Labcorp Genetics (formerly Invitae), Labcorp RCV000696813 SCV000825392 uncertain significance Breast-ovarian cancer, familial, susceptibility to, 4 2022-11-15 criteria provided, single submitter clinical testing In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown this variant is associated with skipping of exon 3, but one or more of the resulting mRNA isoform(s) may be naturally occurring (PMID: 30623411; Invitae). ClinVar contains an entry for this variant (Variation ID: 492412). This variant has not been reported in the literature in individuals affected with RAD51D-related conditions. This variant is present in population databases (rs201974522, gnomAD 0.007%). This sequence change falls in intron 2 of the RAD51D gene. It does not directly change the encoded amino acid sequence of the RAD51D protein. It affects a nucleotide within the consensus splice site.
Ambry Genetics RCV000584627 SCV002698217 uncertain significance Hereditary cancer-predisposing syndrome 2024-11-19 criteria provided, single submitter clinical testing The c.145-3C>T intronic variant results from a C to T substitution 3 nucleotides upstream from coding exon 3 in the RAD51D gene. This nucleotide position is well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing. RNA studies have demonstrated that this alteration results in an incomplete splice defect involving exons excluded from naturally occurring transcripts; the clinical impact of this abnormal splicing is unknown at this time (Ambry internal data). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.